SCHEMBL878650

SCHEMBL878650

CS(=O)(=O)Nc1cccc(-c2cnc3[nH]cc(C(=O)c4cc(O)cc(O)c4)c3c2)c1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TNIK Q9UKE5 7/20 0.54
CLK1 P49759 1/20 0.52
DYRK1A Q13627 1/20 0.52
DYRK2 Q92630 1/20 0.52
DYRK1B Q9Y463 1/20 0.52
PIK3CA P42336 2/20 0.51
AAK1 Q2M2I8 1/20 0.49
CYP2C19 P33261 2/20 0.47
CYP2C9 P11712 1/20 0.47
AXL P30530 1/20 0.47
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
HPGD P15428 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CAMKK2 Q96RR4 2/20 0.46
BTK Q06187 3/20 0.46
ITK Q08881 3/20 0.46
NTRK1 P04629 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL878738 0.93 TNIK (0.55) TNIKCLK1DYRK1ADYRK2DYRK1B
SCHEMBL414867 0.89 TNIK (0.53) TNIKCLK1DYRK1ADYRK2DYRK1B
SCHEMBL416872 0.88 TNIK (0.56) TNIKPIK3CAAAK1AXLCYP2D6
SCHEMBL857599 0.87 BRAF (0.54) TNIKPIK3CAAAK1CYP2C19CYP2C9
SCHEMBL298800 0.87 TNIK (0.54) TNIKCLK1DYRK1ADYRK2DYRK1B
SCHEMBL3706659 0.87 INSR (0.55) TNIKCLK1DYRK1ADYRK2DYRK1B
SCHEMBL415675 0.85 CYP2C9 (0.52) TNIKCLK1DYRK1ADYRK2DYRK1B
SCHEMBL413621 0.85 TNIK (0.53) TNIKCLK1DYRK1ADYRK2DYRK1B
SCHEMBL8388658 0.84 TNIK (0.52) TNIKCLK1DYRK1ADYRK2DYRK1B
SCHEMBL413564 0.84 TNIK (0.52) TNIKPIK3CAAAK1CYP2C19CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143271-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2012-03-27 US disclosed
US-20120053177-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2012-03-01 US disclosed
US-20120022098-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2012-01-26 US disclosed
US-20110059963-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. 2011-03-10 US disclosed
US-7863288-B2 protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents PLEXXIKON, INC. (US) 2011-01-04 US disclosed
US-20100256365-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. 2010-10-07 US disclosed
US-20100249118-A1 protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents PLEXXIKON INC. 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249118-A1 protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents MAP4K1, MAP4K2, MAP3K1 TNIK 218/4885CLK1 406/4885DYRK1A 646/4885
US-20120053177-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, MAP3K13, MAP3K8 TNIK 313/4885CLK1 415/4885DYRK1A 604/4885
US-20120022098-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, MAP3K13, MAP3K8 TNIK 313/4885CLK1 415/4885DYRK1A 604/4885
US-20110059963-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, MAP3K13, MAP3K8 TNIK 313/4885CLK1 415/4885DYRK1A 604/4885
US-20100256365-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, MAP3K13, MAP3K8 TNIK 313/4885CLK1 415/4885DYRK1A 604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.